Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure (Q28327140)

From Wikidata

Jump to navigation Jump to search

scientific article published on June 1, 1991

Language	Label	Description	Also known as
English	Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure	scientific article published on June 1, 1991

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Phosphodiesterase III inhibition or adrenoreceptor stimulation: milrinone as an alternative to dobutamine in the treatment of severe heart failure (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure (English)

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

0 references

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

author name string

G. Mager

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

R. K. Klocke

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

A. Kux

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

H. W. Höpp

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

H. H. Hilger

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1852090

10 December 2022

language of work or name

0 references

publication date

1 June 1991

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

full work available at URL

https://api.elsevier.com/content/article/PII:0002870391908345?httpAccept=text/xml

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

https://api.elsevier.com/content/article/PII:0002870391908345?httpAccept=text/plain

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

121

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

6 Pt 2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

1974-1983

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure

1

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparative hemodynamic effects of dopamine and dobutamine in patients with acute cardiogenic circulatory collapse.

2

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

[Combination of dopamine and dobutamine in the differential therapy of acute and chronic myocardial failure]

3

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Drugs five years later. Dobutamine

4

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Myocardial metabolic and hemodynamic effects of dobutamine in heart failure complicating coronary artery disease

5

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock

7

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy

8

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Dobutamine in chronic ischemic heart failure: Alterations in left ventricular function and coronary hemodynamics

9

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The effect of dobutamine on myocardial performance and high-energy phosphate metabolism at different stages of heart failure in cardiomyopathic hamsters: a 31P MRS study

10

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Subsensitivity of beta responses during therapy with a long-acting beta-2 preparation

11

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure

12

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Catecholamine-induced subsensitivity of adenylate cyclase associated with loss of beta-adrenergic receptor binding sites

13

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Tolerance to dobutamine after a 72 hour continuous infusion

15

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intravenous use of enoximone.

19

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparison of acute hemodynamic response to dobutamine and intravenous MDL 17,043 (enoximone) in severe congestive heart failure secondary to ischemic cardiomyopathy or idiopathic dilated cardiomyopathy

20

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intravenous use of amrinone for the treatment of the failing heart

22

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study.

24

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure

25

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.

26

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone

27

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

28

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure

29

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Drug- and disease-induced changes of human cardiac beta 1- and beta 2-adrenoceptors

30

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failure

32

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy

33

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition

34

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Differential effects of milrinone and dobutamine on right ventricular preload, afterload and systolic performance in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

36

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure

38

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure

40

1 reference

10.1016/0002-8703(91)90834-5

https://api.crossref.org/works/10.1016/0002-8703(91)90834-5

10 December 2022

Identifiers

10.1016/0002-8703(91)90834-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1852090%20AND%20SRC:MED&resulttype=core&format=json

19 September 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28327140&oldid=1787339865"